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Abstract
Background and Aims: Meningococcal disease remains one of the most important infectious causes of death in
industrialized countries. The highly diverse clinical presentation and prognosis of Neisseria meningitidis infections are the
result of complex host genetics and environmental interactions. We investigated whether mitochondrial genetic
background contributes to meningococcal disease (MD) susceptibility.
Methodology/Principal Findings: Prospective controlled study was performed through a national research network on MD
that includes 41 Spanish hospitals. Cases were 307 paediatric patients with confirmed MD, representing the largest series of
MD patients analysed to date. Two independent sets of ethnicity-matched control samples (CG1 [N=917]), and CG2
[N=616]) were used for comparison. Cases and controls underwent mtDNA haplotyping of a selected set of 25 mtDNA SNPs
(mtSNPs), some of them defining major European branches of the mtDNA phylogeny. In addition, 34 ancestry informative
markers (AIMs) were genotyped in cases and CG2 in order to monitor potential hidden population stratification. Samples of
known African, Native American and European ancestry (N=711) were used as classification sets for the determination of
ancestral membership of our MD patients. A total of 39 individuals were eliminated from the main statistical analyses
(including fourteen gypsies) on the basis of either non-Spanish self-reported ancestry or the results of AIMs indicating a
European membership lower than 95%. Association analysis of the remaining 268 cases against CG1 suggested an
overrepresentation of the synonym mtSNP G11719A variant (Pearson’s chi-square test; adjusted P-value=0.0188; OR [95%
CI]=1.63 [1.22–2.18]). When cases were compared with CG2, the positive association could not be replicated. No positive
association has been observed between haplogroup (hg) status of cases and CG1/CG2 and hg status of cases and several
clinical variants.
Conclusions: We did not find evidence of association between mtSNPs and mtDNA hgs with MD after carefully monitoring
the confounding effect of population sub-structure. MtDNA variability is particularly stratified in human populations owing
to its low effective population size in comparison with autosomal markers and therefore, special care should be taken in the
interpretation of seeming signals of positive associations in mtDNA case-control association studies.
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Introduction
The clinical presentation of meningococcal infections caused by
Neisseria meningitidis is highly diverse. Invasive infections usually
result in meningococcaemia, meningitis, or both [1,2]. Meningo-
coccal disease (MD) remains one of the most important infectious
causes of death in industrialized countries [1,2]. Mortality rates
of patients with severe meningococcal sepsis may reach up to
40–50%, and those that survive may have severe complications
that often require amputation and/or skin grafting [2]. The
bacterium, Neisseria meningitidis, is only found in human hosts, and
asymptomatic carriage can exceed 70% during outbreak situations
[3]. The pathophysiology consists of a complex interaction of
bacterial and host factors, triggered mainly by the release of
endotoxin [3]. Individual response to meningococcal lipopolysa-
charides involves also non-immunological mechanisms and the
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system, the coagulation and fibrinolysis pathways, and the
inflammatory reaction mediated by different cytokines and
chemokines [4]. Besides, many studies already support the idea
that genetics plays an important role in MD (see [5] for a recent
review). In this sense, we might hypothesize that mitochondrial
genetic background could be one of these host genetic factors
determining the response to Neisseria meningitides infection and the
individual course of meningococcal disease.
Mitochondrions contain multiple copies of mtDNA genomes.
Each double-stranded circular mtDNA molecule consists of
approximately 16569 base pairs (bps) encoding 37 genes: thirteen
polypeptides (subunits of Complex I, III, and IV plus the ATP
synthase complex), two ribosomal RNAs (rRNAs), and 22 transfer
RNAs (tRNAs). The mtDNA is inherited through the matriline as
a haplotypic block. In the jargon of population geneticists, clusters
of closely-related mtDNA haplotypes are known as haplogroups
(hgs). During the last two decades, population geneticists have
comprehensively investigated the evolutionary patterns of world-
wide mtDNA hgs, so that nowadays there is good knowledge of the
global mtDNA phylogeny and the polymorphisms defining main
and minor branches of the tree (basal motifs) (see e.g.
[6,7,8,9,10,11,12,13,14,15]), as well as positional-mutation rates
[16]. On the other hand, several sporadic or inherited mtDNA
mutations are responsible for a number of mtDNA diseases
(Leber’s hereditary optic neuropathy [LHON], Leigh syndrome,
etc) [17,18]. In addition, genetic variation of mtDNA has also been
linked to several multi-factorial diseases (e.g. [19,20]) although
some of their conclusions have been questioned (e.g. [7,11,21]).
The mtDNA variation has already been investigated in several
infectious diseases. For instance, in an adult AIDS clinical trials
group study, Hulgan et al. [22] claimed that the typically
European hg T was involved in peripheral neuropathy during
antiretroviral therapy. The results of Hendrickson et al. [23]
suggest that mitochondrial genes are important indicators of AIDS
disease progression in HIV-1 infected persons. Houshmand et al.
[24] did not detect statistical significant differences between
tuberculosis patients (N=54) and a control group (N=256) in a
case-control study. MtDNA predisposition to sepsis has also been
investigated in several studies. Thus, Baudouin et al. [25], by
analysing 150 individuals who were sequentially admitted to an
intensive care unit in the UK and 542 age-matched controls,
determined that mtDNA hg H was a strong independent predictor
of outcome during severe sepsis, conferring a 2.12-fold (95% CI
1.02–4.43) increased chance of survival at 180 days compared
with individuals without hg H. More recently, Yang et al. [26]
claimed that hg R can predict survival advantage in severe sepsis, a
conclusion derived from the prospective analysis of 181 Han
patients recruited in an intensive care unit.
There are major causes of type I errors in population-based
association studies, such as hidden population sub-structure or
inadequate correction for multiple testing [27,28,29,30,31,32,33].
The confounding effect of population sub-structure is particularly
problematic in mtDNA studies because variation is strongly
stratified in populations owing to its smaller effective population
size in comparison with autosomal markers. For instance, it is well
known from population genetic studies that several mtDNA
variants are strongly stratified in the Iberian Peninsula, such as hg
V, H1a, H3 and H5 that are highly prevalent in the Franco-
Cantabrian refugee [6,34,35,36]; therefore, the Spanish popula-
tion cannot be considered a single homogeneous population.
Multi-centric studies involving dozens of laboratories and different
medical specialists can help to add extra ‘noise’ to the sampling
collection; for instance, the use of subjective criteria to assign
ethnic classes to patients or assignment of ethnicity based on self-
reported ancestry [37,38] might contribute to increase stratifica-
tion in mtDNA studies.
The present study aims to evaluate the potential pathogenic role
of well-known mtDNA variants in MD. In contrast with most
typical mtDNA case-control association studies, the additional
goal of the present project was to further investigate the effect of
confounding factors (such as stratification) in determining the
apparent association of particular variants with the disease.
Results
Ancestry Assessment of Patients
Analysis of ancestry in patients was assessed by use of a
classification group of population samples of known African,
American, and European ancestry. As indicated in Figure 1, most
of the cases have European ancestry; the average European
membership in cases was 95% (SD: 10%), virtually equal to the
values obtained for a typical European dataset. PCA plot (Figure 1)
indicates that meningococcal patients clearly cluster in a single
group, as evidenced also by the African and American samples.
The amount of variation accounted by the PC1, PC2, and PC3
was ,29%, ,17%, and 13% respectively; ,59% in total.
Evaluating the Potential Association of mtDNA
Haplogroups and Clinic-Pathological Variants
A total of 39 individuals were eliminated from the main
statistical analyses (including fourteen gypsies) on the basis of non-
Spanish self-reported ancestry or based on the results of AIMs
indicating European membership lower than 95%. Association
analysis was performed for the remaining 268 cases against CG1
(N=917). The power to detect odds ratios as low as 1.6 for
mtSNPs and considering an average population minimum allele
frequency (MAF) of 20% (lower than the average MAF in CG1)
was 92%. Pearson’s chi-square or Fisher’s exact tests were used to
assess association. We adjusted for multiple tests by implementing
a permutation procedure as done in [21] and using 20,000
permutations. Association analysis of cases with CG1 suggested an
overrepresentation of the synonym mtSNP G11719A variant
(Pearson’s chi-square test; adjusted P-value=0.0188; OR [95%
CI]=1.63 [1.22–2.18]) with respect to CG1 (Table 1). The logical
way to confirm this positive association is to explore a second
independent sample of patients. Because, however, the prevalence
of the MD is low (in contrast with other common complex
diseases), recruitment of a second independent sample was not
possible. The present study is in fact, to our knowledge, the largest
series of MD patients analysed to date in genetic studies. The
alternative way to replicate the association of G11719A variant
with the disease is to explore a second sample of controls.
Therefore, cases were compared against a second series of
ethnicity-matched controls (CG2; N=616); the power to detect
ORs as low as 1.6 for mtSNPs (MAF=20%) using CG2 was 88%
(Table 1). The association of G11719A observed in comparison of
cases and CG1 could not be replicated with CG2. Instead, the
A4769G variant appears as statistically significant, although
marginal (Pearson’s chi-square test; adjusted P-value=0.0469)
given a nominal value of significance of a=0.05.
Analysis of population mtDNA data obtained from healthy
individuals representing several Spanish geographical regions
supports the spurious nature of the seeming positive association
found in cases versus CG1 for the polymorphism G11719A (Text
S1). The seeming association could be most likely due to the
confounding effect of population stratification; in particular, the
frequency of G11719A in CG1 is unusually low (Text S1). Other
mtDNA hgs in MD
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in mtDNA case-control disease studies are commented in Text S1.
Analysis of association between hg status of patients and
controls was also carried out (Table 2).The best P-value was
obtained for hg R (0.005), which is however non statistically
significant when correcting for multiple test using Bonferroni
(adjusted significant value a= 0.00058).
Among the several clinical variables analysed in the present study
(Table 3), acute respiratory distress syndrome (ARDS) was found to be
strongly associated with hg U (multinomial logistic regression; un-
adjusted P-value=0.0025) being a strong predictor of increasing risk
to ARDS (OR [95% CI]=12.58 [2.41–64.93]); however, this
association was lost when we adjusted the model using Bonferroni’s
correction and considered the full set of hypotheses tested in the study.
Discussion
Recent studies indicate that mitochondrial dysfunction plays a role
in the pathogenesis of a number of human diseases. Variation in the
mtDNA genome has been suggested as a risk factor in several
complex and common multi-factorial diseases. The present study
aimed to analyse the potential role of several known mtSNPs as
susceptibility factors in MD. We first filtered out from the statistical
analysis the non-Spanish patients (excluding also those patients with
non-Spanish mothers and/or grandmothers). Patients with a non-
European self-reported ancestry or a non-European genetic back-
ground, assessed by a set of AIMs in cases and CG2, were also
excluded from the study. These two initial criteria were rigorously
applied in all patients in order to reduce as much as possible the
potential confounding effect of hidden population stratification.
Statistical analysis of cases and CG1 indicated that polymorphism
G11719A could be a strong indicator of susceptibility risk to MD. A
second round of analyses using an independent series of controls
(CG2) could not, however, confirm the initial finding, and instead
suggested another mtSNP candidate with a marginal significant P-
value, namely A4769G.We claim that the most plausible scenario that
would explain this ambiguous result is the effect of residual hidden
population stratification that could not be ‘erased’ by use of the tools
described above because (i) the AIMs employed in the present study
were not originally designed to detect differences within European
Figure 1. Analysis of population sub-structure in MD cases. On the left, analysis of population structure in CEPH panel samples (including 225
Africans, 208 Native Americans and 278 Europeans; see text for more details), and 307 meningococcal patients, based on a 34-plex autosomal AIMs
for the assignment of ancestral origin with grouping values of K=3. Top panel (A) is the representation of membership of the samples as originally
introduced in the analysis; the bottom panel (B) shows the same samples sorted by membership values. On the right, Principal Component Analysis
of the same samples used in Text S1. PC1, PC2, and PC3 stand for principal components one, two and three, respectively; in rounded brackets is the
amount of variation accounted by each component.
doi:10.1371/journal.pone.0008347.g001
mtDNA hgs in MD
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variation within Iberia; to our knowledge, such an ideal panel able to
detect stratification on the geographic scale considered in the present
study does not exist; and (ii) it is also possible that the detection of
stratification using autosomal SNPs (e.g. Genomic Control) [32,53,54]
is not at the level of resolution needed to detect population sub-
structured patterns in mtDNA variability. Moreover, a proper
implementation of a Genomic Control would require the use of
various hundreds of autosomal SNPs (especially in markers strongly
stratified as it is the case of mtDNA), which contrast with the few SNPs
that are usually interrogated in case-control mtDNA studies. The use
of AIMs, as done in the present study, could be a reasonable solution
at least to detect obvious (genomic) outliers, but a more sensitive set of
AIMs would be needed to detect stratification at the level of more
homogeneous populations such as those from Spain mainland.
Our study concludes that mtDNA does not seem to play a role
in MD susceptibility, course or prognosis; at least from the point
of view of the mtSNPs analyzed in the present study and the
population samples considered. However, the present study
indicates that evidences of positive associations can arise from
deficient sampling procedures or a lack of special care in
consideration of the potential confounding effects of population
sub-structure in mtDNA studies. In our particular study, it was
not possible to recruit a second independent collection of cases,
owing to the relatively low prevalence of MD; note however that
the present study is, to our knowledge, the largest MD cohort
analysed to date for a genetic condition. This fact led us to
consider a second group of matched controls to replicate the
positive signal of association observed in the first control group;
however, this time our best candidate mtSNP did not show
evidences of association. Therefore, the use of two different
control groups from the Iberian Peninsula has allowed us to rule
out the presumable association of G11719A with MD. In
addition, the use of a moderate approach to correct the
undesirable effect of multiple tests in the inflation of type I error
has also allowed us to avoid false claims of association of hg U
with ARDS, a serious reaction to various forms of injuries to the
lung and strongly related to MD patients. Our results also
indicate that genotyping bias could also contribute undesirably to
a false positive result in mtDNA association studies (see Text S1).
Random variation of the test statistics could also explain at least
in part the discrepancy observed between CG1 and CG2.
Table 1. Pearson’s chi-square test for cases versus CG1 and CG2.
MD cases versus CG1 MD cases versus CG2
SNP
rCRS
ref.
MAF
cases MA MAF
Chi2
exact P-value
adjusted
P-value OR (95% CI) MAF
Chi2
exact P-value
adjusted
P-value OR (95% CI)
G3010A G 0.28 A 0.29 1.2372 0.266 0.9918 0.83 (0.61–1.15) 0.28 0.3997 0.527 1 0.90 (0.64–1.25)
T3197C T 0.06 C 0.06 0.0356 0.85 1 0.95 (0.53–1.68) 0.10 4.0081 0.045 0.532 1.78 (1.01–3.14)
G3915A G 0.02 A 0.02 0.8348 0.361 0.999 0.57 (0.17–1.94) 0.04 4.8407 0.028 0.374 0.28 (0.08–0.94)
C3992T C 0.01 T 0.01 0.1432 0.705 1 0.78 (0.22–2.77) 0.01 0.0008 0.977 1 0.98 (0.25–3.82)
T4216C T 0.17 C 0.18 0.0647 0.799 1 0.95 (0.66–1.37) 0.16 0.1798 0.672 1 0.92 (0.62–1.35)
T4336C T 0.02 C 0.03 2.3434 0.127 0.8886 0.40 (0.12–1.35) 0.04 4.8627 0.027 0.3628 0.28 (0.08–0.94)
A4529T A 0.02 T 0.02 0.1596 0.69 1 1.21 (0.47–3.10) 0.00 10.2116 0.004 0.0659 14.04 (1.68–
117.18)
G4580A G 0.04 A 0.04 2.8558 0.091 0.7941 0.60 (0.33–1.09) 0.03 4.5172 0.034 0.4381 0.49 (0.25–0.96)
A4769G A 0.02 A 0.02 0.0002 0.989 1 0.99 (0.36–2.72) 0.00 11.2448 0.003 0.0469 –
A4793G A 0.00 G 0.00 7.1652 0.007 0.1121 – 0.01 0.0735 0.786 1 0.80 (0.16–4.00)
T6776C T 0.08 C 0.09 0.9034 0.342 0.9988 0.77 (0.46–1–32) 0.04 2.4415 0.118 0.8732 1.62 (0.90–3.01)
C7028T C 0.47 T 0.49 6.1755 0.013 0.2 1.42 (1.08–1.87) 0.45 1.3431 0.246 0.9906 1.19 (0.89–1.59)
G8994A G 0.02 A 0.02 2.3745 0.123 0.8827 1.90 (0.83–4.35) 0.02 2.6354 0.105 0.8395 2.10 (0.84–5.22)
G9055A G 0.06 A 0.06 2.7059 0.1 0.8244 1.53 (0.92–2.55) 0.10 0.1954 0.658 1 0.89 (0.54–1.48)
A10398G A 0.19 G 0.18 1.4671 0.226 0.9835 1.23 (0.88–1.73) 0.20 0.4369 0.509 1 1.13 (0.79–1.61)
C10400T C 0.01 T 0.01 2.6015 0.107 0.8459 2.30 (0.81–6.53) 0.01 2.2218 0.136 0.9139 2.32 (0.74–7.27)
T10463C T 0.10 C 0.10 0.0700 0.791 1 1.06 (0.68–1.67) 0.09 0.6038 0.437 0.9999 1.21 (0.74–1.97)
C10873T C 0.03 C 0.02 4.9968 0.025 0.3374 0.46 (0.22–0.92) 0.04 0.6441 0.422 0.9999 0.75 (0.38–1.51)
G11719A G 0.41 A 0.38 10.7820 0.001 0.0188 1.63 (1.22–2.18) 0.47 0.3430 0.558 1 1.09 (0.82–1.46)
A12308G A 0.17 G 0.18 0.6261 0.429 0.9998 0.86 (0.59–1.25) 0.24 7.7546 0.006 0.0927 0.59 (0.40–0.86)
C12705T C 0.09 T 0.08 6.5570 0.01 0.1549 1.75 (1.14–2.71) 0.07 7.1341 0.010 0.1533 1.89 (1.18–3.03)
G13708A G 0.09 A 0.09 0.6741 0.412 0.9994 0.81 (0.48–1.35) 0.09 0.5517 0.458 1 0.82 (0.48–1.39)
A13966G A 0.02 G 0.01 3.6348 0.057 0.6202 2.35 (0.95–5.81) 0.02 0.4319 0.511 1 1.34 (0.56–3.24)
C14766T C 0.44 C 0.43 4.2540 0.039 0.4805 1.33 (1.01–1.75) 0.48 0.1177 0.752 1 1.05 (0.79–1.40)
T16519C T 0.33 T 0.33 0.4574 0.499 1 1.11 (0.82–1.49) 0.35 1.3385 0.247 0.9911 1.20 (0.88–1.63)
rCRS: allele in the revised Cambridge Reference Sequence (rCRS) [55]; MA: allele with the lowest frequency; MAF: minimum allele frequency computed on control
individuals; Adjusted P-value: adjustment of chi-square P-values was carried out with a permutation-based approach; number of permutations=20,000; OR (95%CI): ORs
were computed with the rCRS allele as a reference.
doi:10.1371/journal.pone.0008347.t001
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of population stratification, even after those patients with a
different genetic background have been filtered out. The risk of
false positives owing to stratification is particularly high in mtDNA
studies because the effective population size of this marker is lower
than autosomal ones, and therefore mtDNA variability is more
deeply structured in human populations. All together, these results
suggest that more sensitive AIMs, suitable for detecting stratifica-
tion within more restricted geographical locations (within the
Spanish territory), would be needed in future studies. Special care
must be taken in mtDNA association studies of multi-factorial
diseases to avoid false claims of association.
Materials and Methods
Ethics Statement
The study was conducted according to the Spanish Law for
Biomedical Research (Law 14/2007- 3 of July) and complied with
the Declaration of Helsinki. The study and the use of archive
samples for this project were approved by the Research Ethics
CommitteeofGaliciaandthe EthicsCommitteeoftheUniversityof
Santiago de Compostela. Written informed consent was obtained
from all patients. All the samples were collected anonymously.
Study Subjects
A prospective controlled study performed through a national
research network on MD (ESIGEM network – http://www.
esigem.org) that includes 41 Spanish paediatric intensive care units
was carried out between January 2006 and July 2008.
Cases were 307 paediatric patients with MD; the mean age at
diagnosis was 3.7 years (SD: 3.9). More than 200 parameters of
clinical interest were obtained from each patient, including
demographic, clinical, analytical, and prognostic data. Among these
variables we included: (1) clinical data such as diagnosis and clinical
presentation, vaccination status, time from starting symptoms to
admission, length of stay at the paediatric critical care unit and at
the hospital ward, mortality, morbidity, treatment, and also two
scores (Paediatric Risk of Mortality Score, and Meningococcal
Septic Shock Score); (2) microbiology data such as serogroup,
serotype and place of isolation; and (3) laboratory data comprising
white and red cells, platelets, glucose, creatine, sodium, potassium,
pH, PaO2/FiO2, calcium, coagulation test and procalcitonine.
However, in order to minimise the number of hypotheses tested,
only a selection of the 25 most important ones was used for
comparison with the hg status of patients (Table 3).
Two different ethnicity-matched control series were used. The first
series (CG1) comprised 917 Spanish individuals, including breast
cancer patients and controls that were previously employed in [21,39];
a sub-sample of the CG1 was previously tested for population
stratification by means of a panel of neutral autosomal SNPs [40]. The
second control series (CG2) included 616 new genotyped Spanish
individuals. A third group composed of 597 sporadic breast cancer
cases and controls (CG3), collected in the Canary Islands, was
additionally used to test some additional hypotheses (see below).
Genotypes in the cases and controls series were re-checked by two
independent analysts in order to minimise the probability of
genotyping errors. Ambiguous calls were eliminated from the analysis.
mtSNP Selection
All the samples were genotyped for a set of 25 mtSNPs, some of
them representing main branches of the European mtDNA
phylogeny, such as hg H, U, K, etc.; the panel fully overlapped
with the mtSNPs genotyped in [21].
Table 2. Pearson’s chi-square test for the hg status of cases versus CG1 and CG2.
HG status in cases versus CG1 HG status in cases versus CG2
HG Freq. Cases Chi2 exact P-value OR (95% CI) Freq. CG1 Chi2 exact P-value OR (95% CI) Freq. CG2
H 0.41 5.2881 0.021 1.38 (1.04–1.82) 0.41 0.9834 0.321 1.16 (0.87–1.55) 0.45
H1 0.20 0.0485 0.826 0.96 (0.68–1.35) 0.20 0.0453 0.831 1.04 (0.73–1.48) 0.21
H3 0.07 1.1113 0.292 1.33 (0.78–2.26) 0.09 1.2397 0.266 0.71 (0.39–1.30) 0.05
HV 0.47 2.4663 0.116 1.24 (0.95–1.63) 0.53 0.0086 0.926 1.01 (0.76–1.35) 0.48
I 0.02 0.0454 0.831 1.11 (0.41–3.01) 0.02 5.6451 0.018 0.17 (0.04–0.89) 0.00
J 0.06 1.1921 0.275 1.36 (0.78–2.39) 0.08 0.6421 0.423 1.27 (0.71–2.29) 0.07
J1 0.04 1.0250 0.311 1.39 (0.73–2.63) 0.06 1.0010 0.317 1.40 (0.72–2.73) 0.06
K 0.08 1.4794 0.224 0.73 (0.44–1.22) 0.06 0.0738 0.786 1.07 (0.64–1.80) 0.09
K1 0.07 1.5110 0.219 0.71 (0.41–1.23) 0.05 0.1968 0.657 1.13 (0.65–1.96) 0.08
R 0.87 8.0561 0.005 1.87 (1.21–2.90) 0.93 7.1341 0.008 1.89 (1.18–3.03) 0.93
R0 0.50 4.3115 0.038 1.33 (1.02–1.75) 0.58 0.0885 0.766 1.04 (0.78–1.39) 0.51
T 0.10 0.1017 0.750 0.93 (0.58–1.47) 0.09 0.4751 0.491 0.84 (0.51–1.38) 0.08
TJ 0.16 0.2749 0.600 1.10 (0.76–1.60) 0.17 0.0008 0.978 1.01 (0.68–1.49) 0.16
U 0.17 0.0244 0.876 1.03 (0.72–1.48) 0.18 4.9115 0.027 1.51 (1.05–2.18) 0.24
U5 0.04 0.6841 0.408 1.31 (0.69–2.49) 0.06 7.6008 0.006 2.39 (1.26–4.51) 0.10
V 0.06 2.8237 0.093 0.60 (0.33–1.09) 0.04 4.4651 0.035 0.50 (0.26–0.96) 0.03
W 0.01 0.2851 0.593 0.93 (0.23–2.34) 0.01 0.1928 0.661 0.76 (0.22–2.61) 0.01
The test was carried out for those (sub)hgs with frequences above 5% in the control groups and also the well-known branches of the West European/Iberian phylogeny
I, V, and W. Note that hg frequencies were inferred using the information from the whole haplotype available; this is why for instance, the frequency of hg R0 does not
match with the frequency of G11719A.
doi:10.1371/journal.pone.0008347.t002
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A panel of 34 autosomal AIMs was used to assess ancestry in
cases and CG2. These SNPs exhibit highly contrasting allele
frequency distributions between major population groups. Assign-
ment of population membership of our Spanish patients into
African, Native American, and European ancestry was assessed by
Table 3. Summary of demographic and clinical data of the children included in the study (n=358/398).
Age (years) 3.7 (3.9)
Sex (M:F ratio) 1.63:1
Definitive diagnosis (%)
& 75% of cases
Serogroup (%)#
B5 7 % #
C4 %
not available / not serogrouped 38%
Ethnicity (%)
Western Europeans 87%
Other ethnicities or population groups 13%
Diagnosis
Meningococcemia 50%
Meningitis 12%
Both 38%
Clinical presentation
Septicaemia 59%
Severe sepsis 11%
Septic shock 30%
Clinical Scores
Meningococal Septic Shock Score (MSSS) 1.4 (2.25)
Glasgow Coma Scale (GCS) 12.9 (2.9)
PRISM score 9.5 (12.5)
Organ involvement / Clinical features (%)*
Purpuric rash 81%
Distal vascular compromise 9%
DIC 35%
Cardiovascular dysfunction 45%
Acute pulmonary lesion 11%
Acute respiratory distress syndrome 8%
Neurological dysfunction 24%
Oligoanuria 18%
Renal dysfunction 10%
Hematological dysfunction 35%
Refractory hypotension 16%
Liver dysfunction 7.5%
Purpuric rash 81%
Outcome
Glasgow Outcome Scale (GOS) 4.8 (0.7)
Pediatric Overall Performance Category (POPC) 1.2 (0.7)
Exitus (%) 16 exitus (4%)
& Isolation of Neisseria meningitidis from a normally sterile site; OR detection of specific meningococcal DNA sequences in a specimen from a normally sterile site by
nucleic acid amplification testing. The rest of subjects fulfilled suggestive criteria (detection of Gram-negative diplococci in Gram’s stain of specimen from a normally
sterile site or from suspicious skin lesion; or high titre immunoglobulin class M (IgM) or significant rise in IgM or immunoglobulin class G (IgG) titres to outer membrane
protein antigens of N. meningitides.
# B serogroup accounted for 91.6% of all serogrouped samples.
*Detected anytime during the illness and defined according to Goldstein et al. Pediatr Crit Care Med 2005;6:2–8.
DIC disseminated intravascular coagulation.
Results are expressed as mean (sd) unless otherwise specified.
doi:10.1371/journal.pone.0008347.t003
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du Polymorphisme Humain; http://www.cephb.fr/) as well as
additional samples from the SNPforID project [41]; all of them were
also genotyped for the same 34-plex panel. These samples
represented the three main ancestral source populations that
would probably have contributed to the present genetic composi-
tion of the Spanish population (considering the existence of recent
immigrants coming mainly from America and Africa), and in
particular to our sample of MD patients. Genotypes were retrieved
with the SNPforID browser (http://spsmart.cesga.es/snpforid.php;
[42]; see also [43]). The final sets of samples used for the inference
of individual ancestry were as follows: Africa (N=225), including
Biaka Pygmy (Central African Republic; N=23), Mbuti Pygmy
(Democratic Republic of Congo; N=13), Bantu-speakers from
Kenya (N=11), Mozambique (N=60), San (Namibia; N=6),
Yoruba (Nigeria; N=22), Mandenka (Senegal; N=22), Somalia
(N=60), South African Bantu (N=8); America (N=208), including
Karitiana (Brazil; N=14), Surui (Brazil; N=8), Awa (Colombia;
N=38), CEPH-Colombians (N=7), Coiyama (Colombia; N=71),
Pijao (Colombia; N=35), Maya (Mexico, N=21), Pima (Mexico,
N=14); and Europe (N=278), including Denmark (N=60),
French-Basques (France, N=24), France (N=28), Sardinia (Italy,
N=28), Tuscany (Italy, N=8), Bergamo (Italy; N=13), Galicians
(North-West Spain; N=60), Orkney Islands (Scotland; N=15),
Russia (N=25), Adygei (Russian Caucasus; N=17).
STRUCTURE v.2.3.1 [33] was used to estimate the proportion
of inferred ancestry of individuals (membership) into Europe,
America, and Africa groups. This information was employed to
monitor the effect of population stratification in association tests.
Runs consisted of 200,000 Markov Chain steps after a burn-in of
length 200,000 with five replicates for each K value from two to
six. The a posteriori probability of K equal to three was virtually one.
AIMs variability was also analysed by Principal Component
Analysis (PCA). A modified version of the R library SNPassoc [44]
that allows for tri-allelic SNP status was used.
Minisequencing Genotyping
All the samples were genotyped according to the protocols
described in [45,46] for the mtSNPs and according to [41] for the
AIMs. In both cases, the genotyping method was based on a
minisequencing SNaPshot approach. MtDNA haplotypes were
checked by a phylogenetic-based approach as performed in
previous studies [47,48,49,50,51], in order to minimise the
probability of genotyping errors.
Association Tests
Associations were assessed for individual mtSNPs by compar-
ison of allele frequencies between cases and controls for the two
control series separately (CG1 and CG2), and with a one degree of
freedom chi-square test, or Fisher’s exact test for cell counts below
five. A permutation test was used to address the issue of multiple
testing in mtSNP association tests. Unconditional logistic regres-
sion was used to model the effect of hg status in clinical variables,
as well as to model the effect of these variables with respect to
ancestry proportions of patients. Multinomial logistic regression
was used to test association in the case of clinical variables of
multinomial nature.
The statistical packages Stata v.8 (http://www.stata.com/) and
R (http://www.r-project.org/) were employed to carry out most of
the statistical analysis. Multinomial logistic regression was
computed by means of the R library vglm.
Power calculations were performed in the Quanto software [52].
Power is computed under allelic principles that do not necessarily
fulfil the specific conditions affecting mtDNA variants. There is
however no other option available that is specifically designed to
compute power in mtDNA case-control disease studies.
Supporting Information
Text S1 Population sub-structure of mtDNA variants.
Found at: doi:10.1371/journal.pone.0008347.s001 (0.29 MB
DOC)
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